Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615
This examiner grants 56% of resolved cases
Jessica N. Worsham has resolved 751 cases in Art Unit 1615. Her allowance rate is 56.3 percent, which is moderate for Tech Center 1600. The median days to allowance is 1077, providing a benchmark for the expected duration of the prosecution process. This 1077-day figure helps practitioners set realistic timelines for their clients.
The interview lift is exceptionally high at 56.3 percent. This suggests that an interview is a transformative step in the prosecution process. Given the initial success rate, an interview appears to be the single most effective way to improve the odds of securing a patent. Practitioners should prioritize direct communication to leverage this substantial boost and move cases toward a successful conclusion.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19209980 | PERSONAL CARE COMPOSITION SUBSTANTIALLY FREE OF ALKYL SULFATE OR ALKYL ETHER SULFATE TYPE OF SURFACTANTS | Non-Final OA | The Procter & Gamble Company |
| 18888534 | STRUCTURED RHEOLOGICAL SOLID PERSONAL CARE COMPOSITION | Non-Final OA | The Procter & Gamble Company |
| 19397956 | TREATMENT OF BLOOD LOSS AT TISSUE WOUND | Final Rejection | P Tech, LLC |
| 18684728 | DIRECT TABLETING AUXILIARY COMPOSITION | Non-Final OA | BASF SE |
| 18560900 | SEED TREATMENT COMPOSITIONS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 17539648 | COMPOSITE PARTICLES AND METHOD OF PRODUCING THE SAME, PERSONAL CARE PRODUCT, PERSONAL CARE PARTICLES AND METHOD OF PRODUCING THE SAME, PERSONAL CARE ARTICLE, AND PERSONAL CARE COMPOSITION | Final Rejection | TOPPAN INC. |
| 17916180 | IMPLANT DEVICES AND METHODS FOR TREATMENT OF CERVICAL CANCER | Non-Final OA | Washington University |
| 18291525 | BIOMATERIALS FOR EMBOLIZATION AND DRUG DELIVERY | Non-Final OA | Regents of the University of Minnesota |
| 17926040 | METHODS AND COMPOSITIONS FOR TREATING A FIBROTIC DISEASE | Non-Final OA | BETH ISRAEL DEACONESS MEDICAL CENTER |
| 18741628 | METHODS OF FORMING STORAGE STABLE MIXTURES | Non-Final OA | DSM IP Assets B.V. |
| 18034969 | NON-CATIONIC SOFT POLYPHENOL NANOCAPSULES FOR EFFECTIVE SYSTEMIC DELIVERY OF SMALL INTERFERING RNA (siRNA) FOR CANCER TREATMENT | Final Rejection | Purdue Research Foundation |
| 18005240 | MEDICAL DEVICES HAVING ANTI-MICROBIAL PROPERTIES AND METHODS FOR MAKING THE SAME | Non-Final OA | Hollister Incorporated |
| 17927168 | METAL-ORGANIC FRAMEWORKS DELIVER SMALL MOLECULES AND BIOMACROMOLECULES FOR CANCER IMMUNOTHERAPY | Non-Final OA | The University of Chicago |
| 18879145 | DISPERSION AND COSMETIC CONTAINING SAME | Non-Final OA | SHIN-ETSU CHEMICAL CO., LTD. |
| 18865572 | PLANT DISEASE CONTROL METHOD | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 17999347 | EPITHELIAL CANCER THERAPEUTIC AGENT | Non-Final OA | OSAKA UNIVERSITY |
| 17754657 | ANTIMICROBIAL COMPOSITION FOR ANIMAL FEED | Non-Final OA | Taminco BV |
| 18447240 | ENCAPSULATED VITAMIN D | Non-Final OA | Nulixir Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy